Skip to main content

and
  1. No Access

    Article

    5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases

    5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers. 5-FU-related toxicities usually include haematological, digestive and cutaneous ...

    Pierre-Yves Cordier, André Nau, Joseph Ciccolini in Cancer Chemotherapy and Pharmacology (2011)

  2. No Access

    Article

    DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

    Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed ...

    Chen Guang Yang, Joseph Ciccolini, Aurore Blesius in Cancer Chemotherapy and Pharmacology (2011)

  3. No Access

    Article

    Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile

    We report here the case of a 19-year-old female patient who suffered from extremely severe toxicities (G4 mucitis, fever, diarrhea, alteration of general state) while undergoing low-dose capecitabine treatment...

    Cedric Mercier, Charlotte Dupuis, Aurore Blesius in Cancer Chemotherapy and Pharmacology (2009)

  4. No Access

    Article

    Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency

    This report here is the case of a 52-year-old male patient who suffered from extremely severe haematological toxicities (G4 neutropenia, G4 thrombocytopenia) while undergoing Xelox (Xeloda + Oxaliplatin) treat...

    Joseph Ciccolini, Cedric Mercier, Laetitia Dahan in Cancer Chemotherapy and Pharmacology (2006)